10x Genomics (NASDAQ:TXG) Releases Quarterly Earnings Results, Beats Estimates By $0.10 EPS

10x Genomics (NASDAQ:TXG) released its quarterly earnings results on Thursday. The company reported ($0.14) EPS for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.10, Zacks reports. 10x Genomics had a negative return on equity of 2.86% and a negative net margin of 3.55%.The business had revenue of $151.04 million for the quarter, compared to analyst estimates of $146.67 million. During the same period in the prior year, the company earned $0.28 EPS. 10x Genomics’s revenue for the quarter was down 12.7% on a year-over-year basis.

Here are the key takeaways from 10x Genomics’ conference call:

• Atera demand exceeded expectations, with booked orders already well above the approximately 40 instruments the company expects to ship in 2026. Management cited broad interest from academia, medical centers, and biopharma, with potential utilization estimated at roughly 2x Xenium levels.
• 10x raised its 2026 revenue outlook to $610 million-$630 million, representing 2%-5% growth excluding non-recurring settlement revenue. Q4 is expected to benefit substantially from Atera shipments, alongside normal seasonal strength.
• Q2 revenue was $151 million, or $149.4 million excluding settlement revenue, up 3% year over year; consumables revenue increased 7%, led by 16% growth in spatial consumables and double-digit growth in single-cell reaction volumes. However, total instrument revenue declined 47% as customers moderated purchases ahead of Atera and tariff changes.
• Management expects a modest sequential revenue decline in Q3 as customers defer Xenium and Visium purchases while preparing for Atera, with the spatial transition dynamics expected to peak during the quarter. Atera demand is strong, but near-term shipments remain constrained by manufacturing capacity.
• Executives characterized AI-driven biological research as a significant structural tailwind, increasing demand for high-quality single-cell and spatial data. The company also highlighted continued Flex Apex momentum, expanding multi-omics capabilities, and new oncology partnerships supporting future clinical applications.

10x Genomics Price Performance

NASDAQ:TXG traded up $6.43 during trading hours on Friday, reaching $52.03. 5,431,241 shares of the stock were exchanged, compared to its average volume of 2,844,127. 10x Genomics has a twelve month low of $11.16 and a twelve month high of $52.22. The firm has a 50 day moving average of $38.81 and a 200 day moving average of $27.45. The stock has a market cap of $6.61 billion, a PE ratio of -306.06 and a beta of 2.03.

Analysts Set New Price Targets

TXG has been the topic of several research analyst reports. Canaccord Genuity Group increased their target price on 10x Genomics from $32.00 to $50.00 and gave the stock a “buy” rating in a report on Tuesday, July 14th. Stifel Nicolaus set a $50.00 price objective on 10x Genomics in a report on Friday. Leerink Partners upped their target price on shares of 10x Genomics from $23.00 to $40.00 and gave the company a “market perform” rating in a research report on Friday, July 17th. Bank of America raised their target price on shares of 10x Genomics from $21.00 to $30.00 and gave the company a “neutral” rating in a research note on Monday, April 20th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of 10x Genomics in a research report on Wednesday, June 24th. Four analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $34.83.

Key Stories Impacting 10x Genomics

Here are the key news stories impacting 10x Genomics this week:

• Positive Sentiment: Q2 results exceeded expectations: 10x Genomics reported an adjusted loss of $0.14 per share, better than the $0.23–$0.24 consensus loss, while revenue of $151.0 million topped estimates near $146.7 million. 10x Genomics Q2 Earnings and Revenues Beat Estimates
• Positive Sentiment: 2026 outlook was raised: Management now expects full-year revenue of $610 million to $630 million, with the midpoint slightly above Wall Street’s approximately $613.8 million forecast. The guidance increase signals confidence in demand and supports the stock’s positive reaction. 10x Genomics Raises 2026 Revenue Outlook
• Positive Sentiment: Gross margin improved: Expansion in gross margin adds to the earnings beat and suggests improving operating leverage, even though the company remains unprofitable.
• Neutral Sentiment: Atera shipments remained around 40 units: The company maintained this shipment level while raising its outlook, but investors may be watching for further acceleration in instrument placements. 10x Genomics Q2 2026 Earnings Call Transcript
• Negative Sentiment: Sales and earnings remain pressured year over year: Revenue declined 12.7% from the prior-year quarter, and the company posted a loss versus prior-year EPS of $0.28. Continued losses and an expected full-year loss remain risks despite the improved outlook.

Insider Activity

In other news, insider Benjamin J. Hindson sold 11,595 shares of the firm’s stock in a transaction dated Friday, May 22nd. The shares were sold at an average price of $24.44, for a total transaction of $283,381.80. Following the completion of the sale, the insider owned 502,000 shares in the company, valued at approximately $12,268,880. This trade represents a 2.26% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Shehnaaz Suliman sold 5,723 shares of the company’s stock in a transaction on Tuesday, June 16th. The shares were sold at an average price of $32.63, for a total value of $186,741.49. Following the completion of the transaction, the director directly owned 31,722 shares in the company, valued at approximately $1,035,088.86. This represents a 15.28% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 91,309 shares of company stock worth $2,581,357. 8.84% of the stock is owned by insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Cibc World Market Inc. increased its position in shares of 10x Genomics by 2.2% in the fourth quarter. Cibc World Market Inc. now owns 63,849 shares of the company’s stock valued at $1,041,000 after acquiring an additional 1,385 shares during the period. New York State Common Retirement Fund boosted its holdings in shares of 10x Genomics by 4.4% during the fourth quarter. New York State Common Retirement Fund now owns 36,017 shares of the company’s stock worth $587,000 after purchasing an additional 1,533 shares during the period. Creative Planning grew its stake in shares of 10x Genomics by 3.0% in the third quarter. Creative Planning now owns 56,874 shares of the company’s stock worth $665,000 after purchasing an additional 1,637 shares during the last quarter. Van ECK Associates Corp grew its stake in shares of 10x Genomics by 85.9% in the fourth quarter. Van ECK Associates Corp now owns 3,668 shares of the company’s stock worth $60,000 after purchasing an additional 1,695 shares during the last quarter. Finally, Martingale Asset Management L P raised its position in 10x Genomics by 3.5% during the 4th quarter. Martingale Asset Management L P now owns 89,006 shares of the company’s stock valued at $1,452,000 after purchasing an additional 3,003 shares during the last quarter. Institutional investors and hedge funds own 84.68% of the company’s stock.

10x Genomics Company Profile

10x Genomics, Inc is a biotechnology company specializing in advanced genomic analysis solutions that enable researchers to explore biology at unprecedented resolution. The company develops and manufactures integrated hardware, consumables and software products for single-cell sequencing and spatial genomics. Its flagship Chromium product line supports applications in single-cell RNA sequencing, immune profiling and genome assembly, while the Visium and Xenium platforms offer spatial transcriptomics and in situ analysis, respectively.

Founded in 2012 and headquartered in Pleasanton, California, 10x Genomics serves a global customer base that includes academic institutions, pharmaceutical and biotechnology companies, and government research organizations.